1280P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)

Qing Zhou(Hunan University of Traditional Chinese Medicine), Yi‐Long Wu(Guangdong General Hospital), C. Chen(BeiGene (China)), Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital), C. Fei(BeiGene (China)), Jiuwei Cui(Jilin University), Hongming Pan(Sir Run Run Shaw Hospital), Daphne Day(Monash Medical Centre), Bo Gao(Blacktown & Mount Druitt Hospital), Xianjun Yu(Zhejiang Cancer Hospital), Lu Yang(Suizhou Central Hospital), Jun Zhao(Peking University), Amy Body(Monash Health), Z. Ma(Zhengzhou University), Xiao Xiang(University of Ottawa)
Annals of Oncology
September 1, 2021
10.1016/j.annonc.2021.08.1882
Cited by 2

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k